Macrocure Selected to Present Scientific Poster at 2013 Symposium on Advanced Wound Care (SAWC)
The poster Dr. Allen will present is titled, “A prospective multi-center 24 week observational study evaluating wound healing outcomes in 131 patients in seven community wound care clinics in the largest HMO In Israel, treated with human activated leukocytes suspension, CureXcell." The poster summarizes the results of a phase-IV study in adult patients with chronic wounds (diabetic foot ulcers, pressure ulcers, venous ulcers, post-operative ulcers), resulting in approximately 70% of the wounds being closed within 24 weeks. The conclusion of the study was that CureXcell appears to be both safe and effective in healing chronic wounds. The poster will be available for viewing throughout the conference.
“We are very proud that Macrocure was chosen to present at SAWC as it provides the company with a wonderful opportunity to demonstrate our revolutionary technology to the world’s leading wound care scientists,” said Nissim Mashiach, President and CEO of Macrocure. “This is yet another indication that our research is advancing the treatment of hard-to-heal wounds and we look forward to continuing to present strong results from the studies and trials we are currently conducting.”
Macrocure will be co-sponsoring an accredited educational session on May 4 at 3:30 p.m. titled, "Today’s Science is Tomorrow’s New Treatment Option: Emerging Cell-Based Therapy for Difficult-to-Heal Wounds." The session will be led by Dr. Vickie R. Driver DPM and Dr. Robert J. Snyder. Dr. Driver is the Podiatric Surgery Division Chief and Research Program Director-Limb Preservation and Wound Healing, VA New England Health Care Division, and is President Elect for the Association for the Advancement of Wound Care (AAWC). Dr. Snyder is the Director of Clinical Research, School of Podiatric Medicine at Barry University in Miami Shores, Florida and the President of the Association for the Advancement of Wound Care.
For more information about the SAWC conference, please visit www.woundheal.org/annual-meeting.
About Macrocure
Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies. Macrocure is pursuing regulatory market approval in North America and Europe. CureXcell is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes in the United States, Canada and Israel. The product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.
About CureXcell®
CureXcell ® is an innovative, advanced wound care product comprised of activated allogeneic immune cells that are superficially injected into the wound bed, once a month.
CureXcell® provides the solution for impaired wound healing by introducing the right combination of activated cells required to restore normal wound healing processes and achieve full wound closure.
Media Contact:
Matthew Krieger
Finn Partners Israel for Macrocure
+972-544-676-950
matthew@finnpartners.co.il